How do you prevent the animal immune system from eliminating the library too rapidly?

We fine-tune both circulation duration and phage dose according to the chosen animal model and target tissue. In many situations, the initial few minutes of circulation are important for establishing binding interactions. We also prioritize phage scaffolds with low immunogenic potential and strong stability in the bloodstream.

Can in vivo screening uncover ligands for targets beyond the vasculature?

Although systemic administration mainly targets vascular endothelium, certain phage formats and circulation strategies enable phages to pass into the interstitial space. This makes it possible to target tumor cells or parenchymal cells within organs, especially in models characterized by enhanced vascular permeability.

Which animal models are supported by Creative Biolabs in vivo platform?

We mainly employ mouse and rat models for discovery studies due to their well-documented physiology. That said, the platform can be adapted to other species depending on clinical relevance and the specific needs of the research program.

How do you control nonspecific background during tissue collection?

We carry out extensive cardiac perfusion using saline or buffer following the circulation phase to flush out unbound phages from the vasculature. This step ensures that phages retrieved from homogenized tissues are genuinely bound or internalized, rather than simply remaining in circulation.

In Vivo Screening Introduction

In vivo Screening Applicability Advantages Our Services FAQs

Technical Overview of In vivo Phage Display

Identifying molecules capable of navigating the immense complexity of a living organism remains a major challenge in modern biopharmaceutics. Although conventional in vitro selection approaches have yielded numerous high-affinity binders, these candidates often fail during preclinical development due to the unpredictable nature of physiological environments. In contrast, in vivo phage display screening has emerged as a transformative strategy for discovering targeting moieties within functional biological systems. By leveraging the circulatory system as the primary selection environment, this technique enables the identification of peptides or antibody fragments that can localize to specific tissues while overcoming systemic barriers such as enzymatic breakdown and nonspecific clearance.

Fig.1 Mouse. (Creative Biolabs Authorized)

In vivo screening represents a specialized form of biopanning in which diverse phage display libraries are introduced directly into living animal models, most commonly via intravenous administration. Unlike static in vitro assays, this approach utilizes the native vascular network as a dynamic selection filter. Once introduced into circulation, individual phage particles distribute throughout the body, interacting with a wide array of molecular components on the vascular endothelium as well as within distinct tissue compartments.

The selection process is governed by the concept of molecular homing. Certain tissues—such as those in the brain, muscle, or tumor microenvironments—display unique vascular signatures. Phage clones bearing ligands that complement these signatures preferentially adhere to the target sites, whereas non-binding clones remain in circulation and are eventually eliminated by the reticuloendothelial system. After a defined circulation period, target organs are harvested and processed to recover the bound phages. These enriched clones are then amplified and subjected to multiple rounds of selection, yielding candidates with enhanced specificity and targeting efficiency.

Engage with Our Lead Scientists to Optimize Your In vivo Discovery Strategy

Applicability and Strategic Scenarios

Fig.2 DNA. (Creative Biolabs Authorized)

The adoption of in vivo selection strategies is particularly essential when the research objective involves complex biological interactions that cannot be replicated in a cell culture flask. Several scenarios necessitate the use of this physiologically relevant platform:

Targeting the Vascular Endothelium

The endothelial lining of blood vessels is highly specialized across different organs. In vivo screening is the gold standard for identifying peptides that home to organ specific vasculature, which is critical for developing tissue targeted drug delivery vehicles.

Overcoming Biological Barriers

Identifying ligands capable of crossing the blood brain barrier (BBB) requires a functional circulatory system and intact tight junctions. In vivo platforms allow for the discovery of transport mechanisms that utilize receptor mediated transcytosis.

Tumor Microenvironment Analysis

Malignant tissues exhibit unique physiological properties, including high interstitial pressure and aberrant angiogenesis. Screening in live tumor models ensures that the identified binders can penetrate the dense extracellular matrix of a solid tumor.

Inflammatory and Vascular Diseases

Conditions such as atherosclerosis or arthritis involve the recruitment of specific immune cells and the expression of adhesion molecules. In vivo selection identifies ligands that can home to these active sites of inflammation under dynamic flow conditions.

Discuss Your Project Specs with Our Team to Optimize Homing Specificity

Strategic Advantages of Live Selection Systems

In vivo phage display provides a level of biological relevance that is unattainable through traditional protein based or assays based on cell. The following advantages highlight its superiority in the discovery of translational candidates:

Preservation of Physiological Context

In vivo screening accounts for the effects of blood flow, shear stress, and the presence of serum proteins. Binders identified through this method are already "pre filtered" for their ability to function in a complex biochemical environment.

Bypassing In vitro Artifacts

Cell membrane states often change when cells are cultured in a dish, leading to the loss of native receptors or the expression of artificial markers. Selection in a live model ensures that the phage interacts with receptors in their true native conformation and glycosylation state.

Simultaneous Assessment of Biodistribution

This technique allows researchers to evaluate the targeting efficiency and the nonspecific accumulation of a library simultaneously. By comparing the phage titers in target versus non target organs, a clear picture of specificity is obtained early in the discovery phase.

Discovery of Novel Ligand Receptor Pairs

In vivo screening does not require prior knowledge of a specific target molecule. By selecting for the functional outcome of "homing," researchers can uncover novel biomarkers and receptors that are uniquely expressed in specific disease states.

Consult with Our Senior Scientists to Refine Your Discovery Roadmap

Specialized Services for Advanced Binder Discovery

Fig.3 Lab test. (Creative Biolabs Authorized)

Creative Biolabs offers a sophisticated suite of services designed to move projects from library design to validated lead. Our expertise in binder discovery from phage display ensures that every screening campaign is optimized for the specific animal model and tissue target of interest.

Phage Display Library Construction Service

We design and generate bespoke libraries in scFv, Fab, or peptide formats, optimized for in vivo use and improved stability.

Phage Display Library Screening Service

Our specialists carry out thorough biopanning across a wide range of tissue types, including tumor models and distinct organ systems.

Monoclonal Antibody Discovery Based on Phage Display

A workflow for identifying therapeutic-grade antibodies with strong and specific targeting properties.

Peptide Discovery via Bacteriophage Display

Enabling the discovery of short, functional peptides suitable for drug delivery and imaging purposes.

Stable Binder Discovery Using Phage Display

Developing candidates with increased resilience to serum proteases, allowing for extended circulation time.

pH-Responsive Binder Discovery Based on Phage Display

Creating binders that can adapt to acidic microenvironments, such as those found in tumors or endosomes.

Internalizing Antibody Discovery via Phage Display

Focused screening to identify ligands that are not only tissue-selective but also capable of cellular uptake for intracellular delivery.

Discuss Your Project Specs with Our Team and Accelerate Your Binder Discovery

FAQs

Q: How do you prevent the animal immune system from eliminating the library too rapidly?
A: We fine-tune both circulation duration and phage dose according to the chosen animal model and target tissue. In many situations, the initial few minutes of circulation are important for establishing binding interactions. We also prioritize phage scaffolds with low immunogenic potential and strong stability in the bloodstream.
Q: Can in vivo screening uncover ligands for targets beyond the vasculature?
A: Although systemic administration mainly targets vascular endothelium, certain phage formats and circulation strategies enable phages to pass into the interstitial space. This makes it possible to target tumor cells or parenchymal cells within organs, especially in models characterized by enhanced vascular permeability.
Q: Which animal models are supported by Creative Biolabs in vivo platform?
A: We mainly employ mouse and rat models for discovery studies due to their well-documented physiology. That said, the platform can be adapted to other species depending on clinical relevance and the specific needs of the research program.
Q: How do you control nonspecific background during tissue collection?
A: We carry out extensive cardiac perfusion using saline or buffer following the circulation phase to flush out unbound phages from the vasculature. This step ensures that phages retrieved from homogenized tissues are genuinely bound or internalized, rather than simply remaining in circulation.

Transform Your Antigen Challenges into Targeted Leads

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: